文拉法辛对阻塞性睡眠呼吸暂停患者呼吸暂停低通气指数的影响:随机双盲交叉研究
这项机制性随机双盲安慰剂对照交叉试验纳入20例OSA患者,睡前服用文拉法辛50 mg或安慰剂。但事后分析提示高觉醒阈值患者AHI改善19%,低觉醒阈值者倾向增加。
要点
- 文拉法辛50 mg睡前服用未显著降低总体AHI或改善SpO2最低值。
- 文拉法辛减少总睡眠时间、睡眠效率和REM睡眠,增加NREM 1期睡眠。
- 事后分析提示高觉醒阈值者AHI改善19%,低觉醒阈值者倾向恶化,需个体化选择。
核心结论
- 在未选择的OSA患者中,文拉法辛同时恶化与改善多种病理生理特征,净效应为零。
- 基于病理生理特征仔细选择患者或联用对抗其觉醒效应的药物,可能获得更稳健的疗效。
研究设计与样本
- 机制性、随机、双盲、安慰剂对照交叉试验,纳入20例OSA患者。
- 患者接受两次夜间多导睡眠监测(间隔≥4天),睡前分别服用文拉法辛50 mg速释片或安慰剂。
- 主要结局为呼吸暂停低通气指数(AHI)和外周血氧饱和度(SpO2)最低值。
关键数值与推荐
- 文拉法辛剂量为50 mg速释片,睡前服用。
- 高觉醒阈值者AHI改善19%(-10.9次/h,-3.9至-17.9);低觉醒阈值者AHI倾向增加+7次/h(-2.0至16)。
临床怎么用
- 目前不推荐对未选择的OSA患者使用文拉法辛改善AHI。
- 未来可基于觉醒阈值、基线AHI和上气道可塌陷性等特征筛选可能获益的患者。
- 需关注文拉法辛对睡眠结构(总睡眠时间、睡眠效率、REM睡眠减少)的不利影响。
局限性
- 样本量小(20例),主要结局未达统计学显著。
- 部分发现来自探索性事后分析,需前瞻性验证。
- 单次睡前给药,未评估长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One of the key mechanisms underlying OSA is reduced pharyngeal muscle tone during sleep. Data suggest that pharmacologic augmentation of central serotonergic/adrenergic tone increases pharyngeal muscle tone. RESEARCH QUESTION: We hypothesized that venlafaxine, a serotonin-norepinephrine reuptake inhibitor, would improve OSA severity. STUDY DESIGN AND METHODS: In this mechanistic, randomized, double-blind, placebo-controlled crossover trial, 20 patients with OSA underwent two overnight polysomnograms ≥ 4 days apart, receiving either 50 mg of immediate-release venlafaxine or placebo before bedtime. Primary outcomes were the apnea-hypopnea index (AHI) and peripheral oxygen saturation (Spo2) nadir, and secondary outcomes included sleep parameters and pathophysiologic traits with a view toward understanding the impact of venlafaxine on mechanisms underlying OSA. RESULTS: Overall, there was no significant difference between venlafaxine and placebo regarding AHI (mean reduction, -5.6 events/h [95% CI, -12.0 to 0.9]; P = .09) or Spo2 nadir (median increase, +1.0% [-0.5 to 5]; P = .11). Venlafaxine reduced total sleep time, sleep efficiency, and rapid eye movement (REM) sleep, while increasing non-REM stage 1 sleep (Pall < .05). On the basis of exploratory post hoc analyses venlafaxine decreased ("improved") the ventilatory response to arousal (-30%; P = .049) and lowered ("worsened") the predicted arousal threshold (-13%; [P = .02]; ie, more arousable), with no effects on other pathophysiologic traits (Pall ≥ .3). Post hoc analyses further suggested effect modification by arousal threshold (P = .002): AHI improved by 19% in patients with a high arousal threshold (-10.9 events/h [-3.9 to -17.9]) but tended to increase in patients with a low arousal threshold (+7 events/h [-2.0 to 16]). Other predictors of response were elevated AHI and less collapsible upper airway anatomy at baseline (|r| > 0.5, P ≤ .02). INTERPRETATION: In unselected patients, venlafaxine simultaneously worsened and improved various pathophysiologic traits, resulting in a zero net effect. Careful patient selection based on pathophysiologic traits, or combination therapy with drugs countering its alerting effects, may produce a more robust response. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02714400; URL: www.clinicaltrials.gov.
引用
- Schmickl CN, Li Y, Orr JE, et al. Effect of Venlafaxine on Apnea-Hypopnea Index in Patients With Sleep Apnea: A Randomized, Double-Blind Crossover Study. Chest. 2020. PMID: 32278781. doi:10.1016/j.chest.2020.02.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。